末期腎臓病の世界市場2020-2027:治療別(移植、透析)、地域別

【英語タイトル】End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplantation, Dialysis), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2020 - 2027

Grand View Researchが出版した調査資料(GV20JN105)・商品コード:GV20JN105
・発行会社(調査会社):Grand View Research
・発行日:2020年4月
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2週間)
・調査対象地域:クローバル
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥624,750見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥939,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、末期腎臓病の世界市場を調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場の要因・動向・範囲、治療別(移植、透析)分析、地域別分析、競争分析など、今後の市場展望をまとめております。
・調査手法・範囲
・エグゼクティブサマリー
・市場の要因・動向・範囲
・末期腎臓病の世界市場規模:治療別(移植、透析)
・末期腎臓病の世界市場規模:地域別
・競争分析
【レポートの概要】

The global end stage renal disease market size is anticipated to reach USD 172.0 billion by 2027, exhibiting a CAGR of 12.4% over the forecast period, according to a new report by Grand View Research, Inc. Increasing number of patients suffering from kidney failure or end stage renal disease and rising prevalence of hypertension and diabetes are driving the market for end stage renal disease.

Chronic kidney disease (CKD) is one of the major causes of increase in the kidney failure rates among patients. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million people in U.S suffer from CKD, whereas globally more than 500 million people (12-18% of world population) are affected. Moreover, at present, the highest prevalence rate of CKD is in China, U.S., Taiwan, Japan, Germany, France, Belgium, Africa, and Rest of Asia. It is also estimated that the number of cases of end stage renal disease or CKD will increase among the elderly population, especially in developing countries, such as China, India, and countries in Africa.

Technological advancements in the treatment of renal failure is another factor expediting the overall market growth. For instance, wearable artificial kidney (WAK) is a portable dialysis device designed to enable patients to live healthier as it controls blood pressure, improves clearance of wastes from the blood, and allows end stage renal disease or CKD patient for a less strict diet, resulting in lower fluid weight gain with less stress on the heart. Thus, WAK has the potential to reduce mortality in dialysis patients, thereby improving an end stage renal disease patient’s quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016 with great success.

Key players in the market for end stage renal disease include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd. For instance, in October 2019, Fresenius Medical Care has received breakthrough device designation by U.S. FDA for its new hemodialysis machine that aims to prevent blood clotting without the use of any medication.

Further key findings from the study suggest:

• Based on treatment, the dialysis segment dominated the market for end stage renal disease in 2019 owing to its ease of use and emergency convenience

• Asia Pacific led the market in 2019 owing to the large population of patients with CKD/ESRD and higher incidence of hypertension and diabetes in the region

• Key players operating in the market include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd.

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Treatment
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume price analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 End Stage Renal Disease Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End Users
3.6 Regulatory Framework
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Growing Prevalence Of Diabetes And Hypertension
3.7.1.2 Introduction Of Technologically Advanced Products
3.7.1.3 Increasing Number Of Patients Suffering From Chronic Kidney Disease
3.7.2 Market Restraints Analysis
3.7.2.1 Risk Of Complications
3.7.2.2 Stringent Regulatory Policies For Dialysis Products
3.8 End Stage Renal Disease: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 Swot Analysis, By Pest
Chapter 4 End Stage Renal Disease Market: Segment Analysis, By Treatment, 2016 – 2027 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2019 & 2027
4.3 Segment Dashboard
4.4 Global End Stage Renal Disease Market, by Treatment, 2016 to 2027
4.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
4.5.1 Dialysis
4.5.1.1 Dialysis market, 2016 – 2027 (USD Million)
4.5.2 Transplantation
4.5.2.1 Transplantation market, 2016 – 2027 (USD Million)
Chapter 6 End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2016 – 2027 (USD Million)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2019 & 2027
6.3 Regional Market Dashboard
6.4 Regional Market Snapshot
6.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
6.5.1 North America
6.5.2 Europe
6.5.3 Asia Pacific
6.5.4 Latin America
6.5.5 Middle East And Africa
6.6 Market Size, & Forecasts, Volume And Trend Analysis, 2016 To 2027
6.7 North America
6.7.1 North America End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.7.2 U.S.
6.7.2.1 U.S. End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.7.3 Canada
6.7.3.1 Canada End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8 Europe
6.8.1 Europe End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8.2 U.K.
6.8.2.1 U.K. End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8.3 Germany
6.8.3.1 Germany End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8.4 France
6.8.4.1 France End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8.5 Italy
6.8.5.1 Italy End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.8.6 Spain
6.8.6.1 Spain End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9 Asia Pacific
6.9.1 Asia Pacific End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9.2 Japan
6.9.2.1 Japan End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9.3 China (Mainland)
6.9.3.1 China (Mainland) End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9.4 India
6.9.4.1 India End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9.5 Australia
6.9.5.1 Australia End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.9.6 South Korea
6.9.6.1 South Korea End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.10 Latin America
6.10.1 Latin America End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.10.2 Brazil
6.10.2.1 Brazil End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.10.3 Mexico
6.10.3.1 Mexico End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.10.4 Argentina
6.10.4.1 Argentina End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.10.5 Colombia
6.10.5.1 Colombia End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.11 Mea
6.11.1 Mea End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.11.2 South Africa
6.11.2.1 South Africa End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.11.3 Saudi Arabia
6.11.3.1 Saudi Arabia End Stage Renal Disease Market, 2016 – 2027 (USD Million)
6.11.4 Uae
6.11.4.1 Uae End Stage Renal Disease Market, 2016 – 2027 (USD Million)
Chapter 7 End Stage Renal Disease Market – Competitive Analysis
7.1 Recent Developments & Impact Analysis, By Key Market Participants
7.1.1 Nipro Corporation
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.3 Vendor Landscape
7.3.1 Key Customers
7.3.2 Key Company Market Share Analysis, 2019
7.3.3 Major Deals And Strategic Alliances
7.3.3.1 New Product Launch
7.3.3.2 Expansion
7.3.3.3 Acquistion
7.3.3.4 Marketing & Promotions
7.3.4 Market Entry Strategies
7.4 Public Companies
7.4.1 Company Market Position Analysis
7.4.2 Competitive Dashboard Analysis
7.4.2.1 Market Differentiators
7.5 Private Companies
7.5.1 List Of Key Emerging Companies
7.5.3 Regional Network Map
7.5.4 Company Market Position Analysis
7.6 Company Profiles
7.6.1 MEDTRONIC
7.6.1.1 Company overview
7.6.1.2 Financial Performance
7.6.1.3 Product benchmarking
7.6.1.4 Strategic initiatives
7.6.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
7.6.2.1 Company overview
7.6.2.2 Financial Performance
7.6.2.3 Product/Service benchmarking
7.6.2.4 Strategic initiatives
7.6.3 B. BRAUN MELSUNGEN AG
7.6.3.1 Company overview
7.6.3.2 Financial performance
7.6.3.3 Product/Service benchmarking
7.6.4 BAXTER INTERNATIONAL, INC.
7.6.4.1 Company overview
7.6.4.2 Financial performance
7.6.4.3 Product benchmarking
7.6.4.4 Strategic initiatives
7.6.5 ASAHI KASEI MEDICAL CO., LTD.
7.6.5.1 Company overview
7.6.5.2 financial performance
7.6.5.3 Product benchmarking
7.6.5.4 Strategic initiatives
7.6.6 CANTEL MEDICAL
7.6.6.1 Company overview
7.6.6.2 Financial performance
7.6.6.3 Product benchmarking
7.6.6.4 Strategic initiatives
7.6.7 BD
7.6.7.1 Company overview
7.6.7.2 Financial performance
7.6.7.3 Product benchmarking
7.6.7.4 Strategic initiatives
7.6.8 NIKKISO CO., LTD
7.6.8.1 Company overview
7.6.8.2 Financial performance
7.6.8.3 Product benchmarking
7.6.8.4 Strategic initiatives
7.6.9 JMS CO. LTD
7.6.9.1 Company overview
7.6.9.2 Financial performance
7.6.9.3 Product benchmarking
7.6.9.4 Strategic initiatives

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. North America end stage renal disease market, by country, 2016 - 2027 (USD Million)
Table 4. North America end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 5. U.S end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 6. Canada end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 7. Europe end stage renal disease market, by country, 2016 - 2027 (USD Million)
Table 8. Europe end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 9. U.K. end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 10. Germany end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 11. France end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 12. Italy end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 13. Spain end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 14. Asia Pacific end stage renal disease market, by country, 2016 - 2027 (USD Million)
Table 15. Asia Pacific end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 16. China end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 17. India end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 18. South Korea end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 19. Australia end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 20. Japan end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 21. Latin America end stage renal disease market, by country, 2016 - 2027 (USD Million)
Table 22. Latin America end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 23. Brazil end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 24. Mexico end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 25. Argentina end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 26. Colombia end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 27. Middle East & Africa end stage renal disease market, by country, 2016 - 2027 (USD Million)
Table 28. Middle East & Africa end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 29. South Africa end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 30. South Arabia end stage renal disease market, by treatment, 2016 - 2027 (USD Million)
Table 31. UAE end stage renal disease market, by treatment, 2016 - 2027 (USD Million)


★調査レポート[末期腎臓病の世界市場2020-2027:治療別(移植、透析)、地域別] (コード:GV20JN105)販売に関する免責事項を必ずご確認ください。
★調査レポート[末期腎臓病の世界市場2020-2027:治療別(移植、透析)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆